Related Experiment Video
Updated: Aug 1, 2025
05:08
Implantation of an Isoproterenol Mini-Pump to Induce Heart Failure in Mice
Published on: October 3, 2019
11.2K
Microbially Produced Imidazole Propionate Is Associated With Heart Failure and Mortality
Antonio Molinaro1, Ina Nemet2, Pierre Bel Lassen3
1Wallenberg Laboratory, Department of Molecular and Clinical Medicine and Sahlgrenska Center for Cardiovascular and Metabolic Research, University of Gothenburg, Gothenburg, Sweden; Sahlgrenska University Hospital, Department of Medicine, Gothenburg, Sweden.
JACC. Heart Failure
|April 28, 2023
Summary
The gut microbial metabolite imidazole propionate (ImP) is elevated in heart failure patients and predicts mortality. This finding highlights ImP as a potential biomarker for cardiovascular disease prognosis.
Area of Science:
- Microbiome research
- Metabolomics
- Cardiovascular disease
Background:
- Gut microbial metabolites significantly influence host health.
- Imidazole propionate (ImP) is linked to insulin resistance and type 2 diabetes.
- The association between ImP and heart failure remains unclear.
Purpose of the Study:
- To investigate the relationship between ImP levels and heart failure.
- To determine if ImP is associated with mortality in patients with cardiovascular disease.
Main Methods:
- Serum ImP levels were measured in two large, independent cohorts (European and North American) comprising patients with varying cardiovascular disease severity.
- Cox regression analyses were employed to assess the impact of ImP on 5-year mortality, adjusting for covariates.
Main Results:
- Elevated ImP levels were independently associated with reduced ejection fraction and heart failure in both cohorts.
- Higher ImP concentrations were a significant independent predictor of 5-year mortality.
Conclusions:
- The gut microbial metabolite ImP is increased in individuals with heart failure.
- ImP serves as a predictor of overall survival in patients with cardiovascular disease.
More Related Videos
Related Concept Videos
01:26Heart Failure Drugs: Inotropic Agents
645
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
645
01:27Heart Failure I: Introduction
28
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
28
01:21Myocarditis I: Introduction
13
Myocarditis is inflammation of the myocardium, which is the muscular layer of the heart.EtiologyMyocarditis has a diverse etiology, including a wide range of infectious and non-infectious causes:Infectious CausesViral: Common viruses include Coxsackie A and B, adenovirus, parvovirus B19, enteroviruses, and influenza A.Bacterial: Examples include infections caused by Streptococcus, Staphylococcus, and Mycoplasma species.Rickettsial: Infections like Rocky Mountain spotted fever can result in...
13
01:29Heart Failure II: Pathophysiology
19
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
19
01:20Mitral Regurgitation I: Introduction
23
Mitral regurgitation is characterized by the backward circulation of blood from the left ventricle to the left atrium during systole, a phase of the cardiac cycle when the heart contracts and pumps blood out of the chambers. This abnormal flow occurs primarily due to the dysfunction of the mitral valve or its supporting structures, which include the mitral leaflets, chordae tendineae, annulus, and papillary muscles.Etiology and Mechanisms:Primary Mitral Regurgitation: This type arises from...
23
01:17Pathophysiology of Heart Failure
1.7K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.7K